ArticleCancers2024

Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.

Kang Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.